Unlock instant, AI-driven research and patent intelligence for your innovation.

Salix babylonica-protofield syndrome marker gene and application thereof

A technology for marker genes and syndromes, which can be used in genomics, DNA/RNA fragments, and microbial determination/examination.

Pending Publication Date: 2022-04-12
上海金翌生物科技有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there are no reports of gene markers in patients with Koyanagi-Harada syndrome

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Salix babylonica-protofield syndrome marker gene and application thereof
  • Salix babylonica-protofield syndrome marker gene and application thereof
  • Salix babylonica-protofield syndrome marker gene and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Example 1 Identification of biomarkers

[0067] In this example, the inventor conducted a study on the fecal samples of 38 patients with Koyanagi-Harada Syndrome and 36 healthy controls, carried out association analysis of the entire intestinal microbial gene, studied and described the distribution characteristics of fecal microbial genes, and obtained the genes in the feces. Element. The inventor obtained approximately 190.2Gb of high-quality healthy person (LC) data and 201.6Gb of high-quality Koyanagi-Harada syndrome patient (AS) sequencing data through experimental sequencing to construct a reference gene set for Koyanagi-Harada syndrome, and constructed it with the IGC gene set A more complete gene set. Metagenome analysis showed that 168 genes were closely related to Koyanagi-Harada syndrome, of which 38 microbial genes were enriched in the gut of healthy people, and 130 genes were enriched in the gut microbes of patients with Koyanagi-Harada syndrome.

[0068] ...

Embodiment 2

[0096] Verification of embodiment 2 gene markers

[0097] In order to confirm that the analysis results in Example 1 can be used as Koyanagi-Harada syndrome gene markers, the gene abundance in the feces of 17 Koyanagi-Harada syndrome patients and 16 healthy people in the verification group was further compared, and the The obtained gene markers are screened according to the verification status. The acquisition and processing of the verification population sequencing data were carried out with reference to Example 1.

[0098] The verification results are as follows: Among the 38 genes enriched in the healthy population, 2 have been verified with high quality in the verification set (p_values<0.05). The p-values ​​of the gene markers enriched in the healthy population in the verification population are as follows 2.

[0099] Table 2

[0100] Gene (Taxonomy) p-values ​​(p_values) Enriched population (enrich) N58_GI_0017314 0.0394674348322114 HD N44_G...

Embodiment 3

[0158] The detection of embodiment 3 individual state

[0159] Forty-five stool samples were used to test the individual status of the sample source.

[0160]Refer to the method in Example 2 to determine the abundance of BA15_GI_0053852, VA1_GI_0075627, BA16_GI_0058798, BA20_GI_0078082, VA34_GI_0040061, N29_GI_0014293, and BA20_GI_0050287 in Table 3 in each stool sample, and determine whether the abundance of these 7 genes in each sample falls into the control. The 95% confidence interval of the abundance of the control group or the healthy control group, the state of the individual corresponding to the sample corresponding to the sample whose abundance of the seven genes all fall into the corresponding range of the disease group is determined to be a patient of Koyanagi-Harada syndrome, and all of them fall into the corresponding range of the healthy group The state of the individual corresponding to the sample in the interval is determined to be a non-Koyanagi-Harada syndrom...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a salix babylonica-protofield syndrome gene marker and application thereof, the salix babylonica-protofield syndrome gene marker comprises at least one of a first gene set, therefore, the invention further provides a kit, the kit comprises a reagent suitable for detecting at least one gene in the first gene set, and the reagent is suitable for detecting at least one gene in the first gene set. The first gene set is composed of the following genes: BA15GI0053852, VA1GI0075627, BA16GI0058798, BA20GI0078082, VA34GI0040061, N29GI0014293 and BA20GI0050287, and the first gene set is composed of the following genes: BA15GI0053852, VA1GI0075627, BA16GI0058798, BA20GI0078082, VA34GI0040061, N29GI0014293 and Wherein genes in the first gene set are in one-to-one correspondence with nucleotide sequences shown in SEQ ID NO: 1-7, and the genes in the first gene set and the corresponding sequences in the SEQ ID NO: 1-7 have no less than 90% of identity. Compared with a healthy individual, the gene provided by the invention is remarkably enriched in a salix babylonica-protofield syndrome patient group, can be used as a distinguishing marker of the healthy group and the salix babylonica-protofield syndrome patient group, and can be used as a marker for detecting and / or treating the salix babylonica-protofield syndrome.

Description

technical field [0001] The present invention relates to the field of biotechnology, specifically, the present invention relates to Koyanagi-Harada syndrome marker gene and its application, more specifically, the present invention relates to a kit, the use of the reagent in the preparation of the kit, for prevention or treatment A pharmaceutical composition or food composition for Koyanagi-Harada syndrome, a method for determining whether an individual has Koyanagi-Harada syndrome, a device for determining whether an individual has Koyanagi-Harada syndrome, a device, and a method for screening drugs. Background technique [0002] Koyanagi-Harada syndrome (Vogt-Koyanagi-Harada, VKH) is also known as uveoencephalitis (Uveoencephalitis) syndrome, also known as uveal meningitis or eye-brain-ear-skin syndrome. It is a blinding eye disease caused by an autoimmune reaction that attacks melanocyte antigens, and often invades organs such as ears, brain (spinal) membranes, hair, and sk...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/11C12Q1/6883G16B20/20
Inventor 陈翔刘晶马玮
Owner 上海金翌生物科技有限公司